2018 SGO Annual Meeting on Women’s Cancer

Gynecologic Cancers

Follow-up Too Short in Ovarian Cancer, Too Long in Other Gynecologic Malignancies

A STANDARDIZED 5-year period of surveillance by a gynecologic oncologist was found to be inadequate for some gynecologic cancers and excessive for others, according to research presented by Robert Do...

Gynecologic Cancers

Expert Point of View: Oliver Dorigo, MD, PhD

COMMENTING ON THE study by Cybulska et al, invited discussant Oliver Dorigo, MD, PhD, of Stanford University, said several important questions still need answers. “Tumor immune scores differ between ...

Gynecologic Cancers

Microenvironment Heterogeneity May Contribute to Lack of Immunotherapy Success in High-Grade Serous Ovarian Cancer

INTER- AND INTRAPATIENT heterogeneity of the tumor microenvironment may explain the limited success of checkpoint blockade thus far observed in patients with advanced high-grade serous ovarian cancer,...

SGO 2018: Participation in Clinical Trials May Overcome Health Disparities in Ovarian Cancer

Participation in clinical trials may overcome health disparities in the treatment of advanced or recurrent ovarian cancer, according to a study presented at the Society of Gynecologic Oncology’s...

SGO 2018: Immunotherapy/PARP Inhibitor Combination Produces Remissions in Ovarian Cancer

A combination of the immunotherapy pembrolizumab (Keytruda) and the DNA repair–blocking agent niraparib (Zejula) can be significantly more effective than either drug alone in women with hard-to-...

SGO 2018: New Data Suggest Cervical Cancer Age-Based Screening Guidelines Should Be Reconsidered

One in five women diagnosed with cervical cancer in the United States will be diagnosed after the age of 65, suggesting that the recommended age to stop cervical cancer screening should be reconsidere...

SGO 2018: Gender Differences May Play a Role in Lack of HPV Vaccination

Parents are less likely to vaccinate adolescent boys than girls with the human papillomavirus (HPV) vaccine, and they are twice as likely to report their main reason as a lack of provider recommendati...

SGO 2018: PARP-7 Protein May Play a Significant Role in Survival for Ovarian Cancer

Patients with ovarian cancer with genetic amplification in the PARP-7 protein survived longer than those without the mutation, according to a presentation at the Society of Gynecologic Oncology’...

Advertisement

Advertisement

Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.